FDA OK for Haupt Pharma’s Italian antibiotics plant

By Gareth Macdonald

- Last updated on GMT

Related tags: Food and drug administration

US FDA clearance for Italian antibiotics production facility is important for global growth says German contract development and manufacturing organisation (CDMO) Haupt Pharma.

A Haupt spokesperson told in-PharmaTechnologist that the site, in Borgo San Michele, Latina, now holds Food and Drug Administration (FDA) approval to make two sterile penicillin products for the US market.

The US market has a great potential, it is important for us to be present. [FDA approval] also shows the high standards of good manufacturing practice at our company​.”

She added that successful inspection “gives a positive signal to the market and potential customers who wish to target the US market and makes clear, that Haupt Pharma is a strong and competent partner​.”

The facility, which was purchased from US drug giant Pfizer last February​, also makes non-beta lactam antibiotics for pharma industry customers on a contractual basis, supplying 80 national markets.

Italian generics

The Latina plant is also approved by Italian authorities to produce generic drugs demand for which is likely to increase, according to Haupt’s spokesperson.

[Although] the use of generics in Italian market is still not comparable to other markets such as Germany or UK…further growth is expected in the near future​,” explaining that, according to a L’uso dei farmaci report, use of generics grew 12 per cent in 2009.

The Italian generics market has traditionally made up a smaller proportion of the nation’s total pharmaceutical sales than other European nations, owing to the extended national patent supplementary certificates in place.

This restricted the sale of generics in Italy for a long time after the product had come off patent in other European countries.

Consequently the market was valued at $809m in 2007, according to a report by Espicom Business Intelligence​, which is less than in Portugal despite total pharmaceutical sales in Italy being six times as much.

However, the market is predicted to grow to $1.8bn by 2012 as big products come off patent and efforts to revise the laws covering generics gain pace.

Related news

Show more

Related products

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Related suppliers

Follow us

Products

View more

Webinars